ANUH PHARMA LTD.

Anuh Pharma Ltd has announced the closure of its trading window for dealing in the company's securities. This closure is effective from Thursday, October 01, 2026, and will remain in effect for 48 hours after the declaration of the un-audited financial results for the quarter and half-year ended September 30, 2026. The decision aligns with SEBI (Prohibition of Insider Trading) Regulations, 2015, and aims to prevent potential insider trading. All designated persons and their immediate relatives are advised not to trade in the company's shares during this period.

Anuh Pharma Limited has received a Demand Order from the Income Tax Department for Assessment Year 2018-19, amounting to ₹9,93,206. The demand is related to disallowances of certain deductions claimed under the Income Tax Act. The company plans to file an appeal before the CIT within the stipulated timelines, asserting that it has strong grounds to contest the order. Anuh Pharma believes there will be no impact on its financial or operational activities.

Anuh Pharma Ltd announced that certain shareholders belonging to the Promoter Group, including Mr. Vikram Kirtilal Shah, Mrs. Kiran Piyush Shah, and Mrs. Kinjal Siddharth Jhaveri, have submitted a withdrawal application. They had previously requested reclassification from 'Promoter & Promoter Group' to the 'Public Category' under Regulation 31A of SEBI (LODR) Regulations, 2015. The company had filed an application with the stock exchanges for this reclassification. However, the individuals have now voluntarily decided to withdraw their request, confirming they will continue to remain part of the Promoter Group. The company has submitted the withdrawal request to the exchanges.

Anuh Pharma Ltd has announced its unaudited financial results for the quarter ended June 30, 2026. The company reported its financial performance for the period, adhering to Ind AS 34 standards. The results were reviewed by the Audit Committee and approved by the Board of Directors on August 7, 2026, and have undergone a limited review by the statutory auditors. The company operates in the Bulk drug and Chemicals segment.

Anuh Pharma's standalone Q1 FY27 (quarter ended 30 June 2026) revenue from operations was ₹193.81 Cr, up a modest 3.9% year-on-year from ₹186.48 Cr, and down 4.1% sequentially from ₹202.12 Cr in Q4 FY26. The topline print is unremarkable; the quarter's story is margin. EBITDA margin expanded to 9.99% from 7.34% a year ago and from 9.22% in the March quarter (+265 bps YoY), taking PBT to ₹16.93 Cr, up 54.6% YoY and 9.1% QoQ even as revenue fell sequentially. Reported PAT of ₹11.42 Cr rose 37.6% YoY (EPS ₹1.14 vs ₹0.83) but slipped 2.2% QoQ from ₹11.68 Cr — the gap between PBT growth and PAT growth is explained by the effective tax rate rising to 32.5% this quarter from 24.2% a year ago and 24.7% in Q4, on a larger deferred tax charge (₹1.37 Cr vs ₹0.16 Cr YoY). Stripped of the tax-rate swing, underlying operating performance was stronger than the PAT line alone suggests. There are no exceptional items in either the current or comparison quarters, so the YoY and QoQ moves are on a like-for-like operating basis. Q4 FY26's other income had absorbed a ₹1.90 Cr mark-to-market loss on investments (Note 6), meaning Q4's underlying core profitability was even better than its ₹11.68 Cr reported PAT — which makes this quarter's sequential dip somewhat more pronounced on a true like-for-like comparison. Finance costs fell to near-zero (₹0.03 Cr vs ₹0.21 Cr YoY), consistent with continued deleveraging. The company operates a single reportable segment (Bulk Drugs and Chemicals) and reported no subsidiaries, associates or JVs as of quarter-end, so standalone is the only basis available. Management has issued no formal guidance in our records or in this filing, and no analyst/street estimates for this quarter were found, so the print cannot be benchmarked against external expectations — it should be read against its own trailing quarters. Aside from the results, the board also approved a revised related-party transactions policy and recorded the withdrawal of reclassification applications by three promoter-group shareholders holding a combined 0.83% stake; neither has a bearing on the P&L.

Anuh Pharma Ltd has announced a Board of Directors meeting scheduled for August 7, 2026. The primary agenda is to consider and approve the Unaudited Financial Results for the quarter ended June 30, 2026. Additionally, the company has closed its trading window for designated persons from July 1, 2026, until 48 hours after the declaration of financial results, which is expected to be August 9, 2026.

Anuh Pharma Ltd has informed the stock exchange about the dispatch of physical communication to shareholders who have not registered their email addresses. This communication provides the web link and navigation path to access the Annual Report for FY 2025-26. The company is also holding its 66th Annual General Meeting on August 12, 2026, via Video Conferencing. Shareholders are encouraged to register their email IDs for electronic communication and consider dematerializing physical holdings.

Anuh Pharma Ltd has submitted its 66th Annual Report for the Financial Year 2025-26, in compliance with SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The report, available on the company's website, details the company's performance and strategic initiatives under the theme 'Foundations for the Future: Building Capacity. Enabling Growth.' The report includes a 10-year financial summary, highlighting key metrics such as Share Capital, Reserves, Borrowings, Gross Block, and Net Block. It also presents the Revenue Account, showing Total Revenue, EBITDA, Profit Before Tax, Profit After Tax, and Earnings Per Share over the past decade. The company also announced a recommended final dividend of ₹1.50 per equity share.

Anuh Pharma Limited has announced the details for its 66th Annual General Meeting (AGM), scheduled to be held on Wednesday, August 12, 2026, at 04:00 p.m. IST. The meeting will be conducted through Video Conferencing (VC) / Other Audio Visual Means (OAVM). Key agenda items include the adoption of audited financial statements for the Financial Year ended March 31, 2026, declaration of a dividend of ₹1.50 per equity share, re-appointment of two directors retiring by rotation (Mr. Bipin Nemchand Shah and Mr. Arun Lalchand Todarwal), ratification of the Cost Auditor's remuneration, and revision in remuneration for Joint Managing Director Mr. Ritesh B. Shah for FY 2026-27.

Anuh Pharma Ltd has announced the closure of its trading window for all designated persons and their immediate relatives. This closure will be effective from Wednesday, July 01, 2026, and will remain in effect for 48 hours after the declaration of the company's un-audited financial results for the quarter ended June 30, 2026. The decision aligns with SEBI (Prohibition of Insider Trading) Regulations, 2015, and aims to prevent potential insider trading activities. Insiders are advised not to trade in the company's securities during this period.